A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial
Por:
Climent M, Font A, Duran I, Puente J, Mendez-Vidal M, Saez M, Lobera C, Arija J, Gonzalez-Del-Alba A, Sanchez-Hernandez A, Fita M, Esteban E, Alonso-Gordoa T, Gonzalez B, Maroto P, Lazaro-Quintela M, Cassinello-Espinosa J, Perez-Valderrama B, Garcias C, Castellano D
Publicada:
1 nov 2022
Ahead of Print:
1 sep 2022
Resumen:
|